SCHEMBL4953186

SCHEMBL4953186

Oc1c2c(nc3ccnn13)CCC2

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 14/20 0.46
HTR2B P41595 13/20 0.46
HTR2A P28223 12/20 0.46
PDE10A Q9Y233 1/20 0.35
LMNA P02545 1/20 0.34
KDM4E B2RXH2 3/20 0.33
MAPT P10636 2/20 0.33
USP2 O75604 1/20 0.33
POLB P06746 1/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TP53 P04637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4958926 0.97 HTR2C (0.46) HTR2CHTR2BHTR2APDE10ALMNA
SCHEMBL4958708 0.95 HTR2C (0.47) HTR2CHTR2BHTR2APDE10ALMNA
SCHEMBL4958921 0.80 HTR2C (0.37) HTR2CHTR2BHTR2APDE10A
SCHEMBL4956864 0.80 HTR2C (0.46) HTR2CHTR2BHTR2APDE10ALMNA
SCHEMBL4955856 0.79 HTR2C (0.40) HTR2CHTR2BHTR2ALMNAKDM4E
SCHEMBL2569024 0.78 HTR2C (0.45) HTR2CHTR2BHTR2APDE10A
SCHEMBL4955234 0.77 HTR2C (0.46) HTR2CHTR2BHTR2APDE10ALMNA
SCHEMBL7843808 0.77 HTR2C (0.46) HTR2CHTR2BHTR2ALMNAKDM4E
SCHEMBL4955065 0.76 HTR2C (0.40) HTR2CHTR2BHTR2ALMNAKDM4E
SCHEMBL4955735 0.75 HTR2C (0.47) HTR2CHTR2BHTR2APDE10ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773345-B1 NON-IMIDAZOLE TERTIARY AMINES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS ATHERSYS INC (US) 2013-12-11 EP disclosed
US-7319103-B2 Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders ATHERSYS, INC. (US) 2008-01-15 US disclosed
EP-1773345-A2 NON-IMIDAZOLE TERTIARY AMINES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS Athersys, Inc. (US) 2007-04-18 EP disclosed
WO-2006004937-A2 NON-IMIDAZOLE TERTIARY AMINES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS ATHERSYS, INC. (US) 2006-01-12 WO disclosed
US-20060009451-A1 Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders ATHERSYS, INC. 2006-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009451-A1 Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders HRH3, HRH4, HRH1 HTR2C 29/4885HTR2B 20/4885HTR2A 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.